Castration-resistant prostate cancer

Potential targets and therapies

Aijaz Parray, Hifzur R. Siddique, Sanjeev Nanda, Badrinath R. Konety, Mohammad Saleem

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.

Original languageEnglish (US)
Pages (from-to)267-276
Number of pages10
JournalBiologics: Targets and Therapy
Volume6
DOIs
StatePublished - 2012

Fingerprint

Castration
Prostatic Neoplasms
Therapeutics
Disease Progression
Prostate
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Chemoresistance
  • CRPC
  • Molecular pathways
  • Neoplastic prostate

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Pharmacology (medical)
  • Gastroenterology
  • Rheumatology

Cite this

Parray, A., Siddique, H. R., Nanda, S., Konety, B. R., & Saleem, M. (2012). Castration-resistant prostate cancer: Potential targets and therapies. Biologics: Targets and Therapy, 6, 267-276. https://doi.org/10.2147/BTT.S23954

Castration-resistant prostate cancer : Potential targets and therapies. / Parray, Aijaz; Siddique, Hifzur R.; Nanda, Sanjeev; Konety, Badrinath R.; Saleem, Mohammad.

In: Biologics: Targets and Therapy, Vol. 6, 2012, p. 267-276.

Research output: Contribution to journalReview article

Parray, A, Siddique, HR, Nanda, S, Konety, BR & Saleem, M 2012, 'Castration-resistant prostate cancer: Potential targets and therapies', Biologics: Targets and Therapy, vol. 6, pp. 267-276. https://doi.org/10.2147/BTT.S23954
Parray, Aijaz ; Siddique, Hifzur R. ; Nanda, Sanjeev ; Konety, Badrinath R. ; Saleem, Mohammad. / Castration-resistant prostate cancer : Potential targets and therapies. In: Biologics: Targets and Therapy. 2012 ; Vol. 6. pp. 267-276.
@article{eeef2613099d470aa87b35764613ad97,
title = "Castration-resistant prostate cancer: Potential targets and therapies",
abstract = "The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.",
keywords = "Chemoresistance, CRPC, Molecular pathways, Neoplastic prostate",
author = "Aijaz Parray and Siddique, {Hifzur R.} and Sanjeev Nanda and Konety, {Badrinath R.} and Mohammad Saleem",
year = "2012",
doi = "10.2147/BTT.S23954",
language = "English (US)",
volume = "6",
pages = "267--276",
journal = "Biologics: Targets and Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Castration-resistant prostate cancer

T2 - Potential targets and therapies

AU - Parray, Aijaz

AU - Siddique, Hifzur R.

AU - Nanda, Sanjeev

AU - Konety, Badrinath R.

AU - Saleem, Mohammad

PY - 2012

Y1 - 2012

N2 - The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.

AB - The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.

KW - Chemoresistance

KW - CRPC

KW - Molecular pathways

KW - Neoplastic prostate

UR - http://www.scopus.com/inward/record.url?scp=84866754770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866754770&partnerID=8YFLogxK

U2 - 10.2147/BTT.S23954

DO - 10.2147/BTT.S23954

M3 - Review article

VL - 6

SP - 267

EP - 276

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

SN - 1177-5475

ER -